Orange Book product · Generic (ANDA)
LOPINAVIR AND RITONAVIR
LOPINAVIR; RITONAVIR
At a glance
Jun 04, 2021
Approved
Generic (ANDA)
Application
AB
TE code
None
Listed patents
Key dates
Approval
FDA approval date of this drug product.
Jun 04, 2021
5 yr 1 mo ago
Today
Pharmaceutical detail
Active ingredient
LOPINAVIR; RITONAVIR
Strength
100MG;25MG
Dosage form
TABLET
Route
ORAL
TE code
AB
Application
ANDA 091677
Product number
001
Marketing status
RX
Reference listed drug (RLD)
No
Reference standard (RS)
No
Active-ingredient family
View full familyGeneric (ANDA) of LOPINAVIR; RITONAVIR
- 2007KALETRABrand (NDA)
NDA 021906 · ABBVIE
- 2000KALETRABrand (NDA)
NDA 021226 · ABBVIE
- 2000KALETRABrand (NDA)
NDA 021251 · ABBVIE
- 2025LOPINAVIR AND RITONAVIRGeneric (ANDA)
ANDA 214696 · MICRO LABS
- 2024LOPINAVIR AND RITONAVIRGeneric (ANDA)
ANDA 204739 · MACLEODS PHARMS LTD
- 2024LOPINAVIR AND RITONAVIRGeneric (ANDA)
ANDA 079074 · MYLAN LABS LTD
- 2022LOPINAVIR AND RITONAVIRGeneric (ANDA)
ANDA 213857 · LAURUS
- 2016LOPINAVIR AND RITONAVIRGeneric (ANDA)
ANDA 207407 · LANNETT CO INC
Listed patents
No patents are listed against this product in the Orange Book. Listed patents reflect those the NDA holder submits under 21 U.S.C. 355 and are not exhaustive.
